Blue Jet Healthcare shares witnessed strong buying interest during Friday's trading session, surging nearly 9% intraday to touch ₹623.35, after the company successfully completed its ₹800 crore Qualified Institutional Placement (QIP). The stock opened 5.83% higher at ₹608, significantly outperforming the 0.88% rise in the NSE Nifty 50 Index. The positive market response indicates strong institutional interest in the qualified institutional placement, with the 10% discount to Monday's closing price indicating the company's efforts to attract institutional investors while maintaining reasonable pricing. The stock has delivered 8% returns on a year-to-date basis and made its market debut in November 2023.
Blue Jet Healthcare has successfully completed its ₹800 crore qualified institutional placement (QIP) with shares closing at ₹575.75, up 2.3% from the previous session. The Investment and Finance Committee approved the allotment of 15,810,276 equity shares to qualified institutional buyers at the issue price of ₹506 per share. As per The Economic Times, the issue price represents a discount of nearly 12% from the stock's closing price on Thursday, with the company's paid-up equity share capital now standing at ₹37.85 crore comprising 18.92 crore equity shares of ₹2 each compared to the previous ₹34.69 crore consisting of 17.35 crore equity shares. The issue price included a premium of ₹504 per share and reflected a discount of ₹25.70, or 4.83%, to the floor price in line with applicable SEBI guidelines for qualified institutional placements. The QIP opened on July 6, 2026, and closed on July 9, 2026.
Nemish Shah, co-founder of Enam Group, has made a significant investment in Blue Jet Healthcare by acquiring nearly 54.34 lakh equity shares in the ₹800 crore QIP. According to investor allotment data, Shamyak Investment Private Limited, which is Shah's primary investment vehicle along with his family, received 34.38% of the total issue size, making it the largest institutional participant. This strategic investment by the veteran investor reflects growing confidence in the pharmaceutical company's prospects and diversification of Shah's investment portfolio beyond traditional sectors.
The QIP saw only two institutions allotted nearly two-thirds of the shares, with the majority going to Shamyak Investment Private Limited (34.38%) which is a systemically important non-banking financial company (SI-NBFC), receiving 54,34,785 equity shares. Other significant participants included ICICI Prudential Value Fund (10.47%) with 16,55,991 shares, ICICI Prudential Manufacturing Fund (8.15%) with 12,87,994 shares, and ICICI Prudential Pharma Healthcare and Diagnostics Fund (5.82%) with 9,19,996 shares each. The remaining allocation was distributed among ICICI Prudential Equity Savings Fund, ICICI Prudential MNC Fund, ICICI Prudential Quality Fund, and ICICI Prudential Quant Fund, with the company's board having earlier secured approval for raising up to ₹1,000 crore through various fundraising routes.
The successful fundraise is expected to strengthen the company's balance sheet, support expansion plans, and boost long-term growth prospects while broadening its institutional shareholder base. As per The Economic Times, the strong participation from institutional investors, particularly multiple schemes managed by ICICI Prudential Mutual Fund, reflects continued institutional interest in Blue Jet Healthcare and its growth prospects. The successful QIP completion and participation from reputed institutional investors has boosted investor sentiment, with market participants viewing the fundraise as a move that could strengthen the company's financial position and provide additional growth capital. The fresh institutional allocation also expanded the company's shareholder base, adding long-term investors to its ownership structure.
For the quarter ended March 2026, the company posted challenging financial results that may have contributed to the fundraising decision. According to reports from Business Standard, Blue Jet Healthcare reported a net profit of ₹64.34 crore in Q4 FY26, down 41.56% year-on-year but up 60.17% quarter-on-quarter. Revenue from operations declined 31.07% YoY to ₹234.67 crore in Q4 FY26 due to negligible sales of one molecule in the PI vertical, though revenue increased 21.96% QoQ from ₹192.41 crore, driven by higher sales of advanced contrast media. EBITDA declined 49% to ₹71 crore, with the EBITDA margin contracting sharply to 30.3% from 41% a year earlier. Profit before tax stood at ₹87.1 crore, compared with ₹147.2 crore in the corresponding quarter last year, while total expenses declined to ₹170.4 crore from ₹205.4 crore.
